Jonathan Miller

“I'll keep my remarks focused on our capital markets activity during the third quarter, the evolution of our expanded shareholder base, and how we're adjusting our investor relations strategy going forward.”

“Q2 was another quarter of continued execution for United States Antimony. We continued our marketing efforts, which included broadening our institutional shareholder base, both domestically and internationally.”

“Our first quarter was another bolt-on period for United States Antimony Corporation. It reflected the acceleration of our strategy, the expansion of our existing platform, and the growing recognition that antimony is no longer a niche industrial input.”

“I guess to what extent or what should we expect from the top line announcements for C-Beyond and then later in the year for C-Forward? What sorts of data should we expect in a top line press release versus what would be withheld for later publication at a medical meeting or in a peer-reviewed setting?”

“I guess looking at a very broad cast development plan here with a lot of combinations across first, second, third line settings, one thing that's notably absent is any approach in the adjuvant setting, which obviously we know Merck is going after.”